Nakaranurack Chotirat, Manosuthi Weerawat
1 Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
2 Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Thailand.
J Int Assoc Provid AIDS Care. 2018 Jan-Dec;17:2325957417752256. doi: 10.1177/2325957417752256.
The prevalence of non-AIDS-related comorbidities is increasing in HIV-infected patients receiving antiretroviral therapy. In Thailand, data regarding the prevalence of non-AIDS comorbidities and factors associated with metabolic complications in HIV-infected patients have not been well-documented.
This cross-sectional study was conducted in 2011 and included 874 HIV-infected patients.
The age of patients was 45(8) years represented as mean (standard deviation [SD]). The current CD4 count was 502(247) cells/mm. In all, 388 (44%) of the included patients had at least 1non-AIDS comorbidity. The most frequently documented comorbidities were hyperlipidemia in 271 (70%) patients. Using multivariate analysis, older age(odds ratio [OR] = 1.82, 95% confidence interval [CI] = 1.51-2.19), male sex (OR = 1.55, 95%CI = 1.14-2.11), high current CD4 count(OR = 1.00, 95%CI = 1.00-1.00), and taking abacavir (ABC)-containing(OR = 2.59, 95%CI = 1.16-5.78)and didanosine (ddI)-containing antiretroviral regimens (OR = 4.16, 95%CI = 1.09-15.84)were associated with the presence of metabolic complications (all Ps<.05).
The prevalence of comorbidities is substantially high. Clinical monitoring and effective management of these comorbidities and metabolic complications are recommended, especially in HIV-infected patients who present with these associated factors.
在接受抗逆转录病毒治疗的HIV感染患者中，非艾滋病相关合并症的患病率正在上升。在泰国，关于HIV感染患者中非艾滋病合并症的患病率以及与代谢并发症相关因素的数据尚未得到充分记录。
这项横断面研究于2011年进行，纳入了874例HIV感染患者。
患者年龄为45（8）岁，以均值（标准差[SD]）表示。当前CD4细胞计数为502（247）个/mm³。总共，388例（44%）纳入患者至少有一种非艾滋病合并症。记录最频繁的合并症是271例（70%）患者的高脂血症。使用多变量分析，年龄较大（比值比[OR]=1.82，95%置信区间[CI]=1.51 - 2.19）、男性（OR = 1.55，95%CI = 1.14 - 2.11）、当前CD4细胞计数高（OR = 1.00，95%CI = 1.00 - 1.00）以及服用含阿巴卡韦（ABC）（OR = 2.59，95%CI = 1.16 - 5.78）和含去羟肌苷（ddI）的抗逆转录病毒方案（OR = 4.16，95%CI = 1.09 - 15.84）与代谢并发症的存在相关（所有P<0.05）。
合并症的患病率相当高。建议对这些合并症和代谢并发症进行临床监测和有效管理，特别是在存在这些相关因素的HIV感染患者中。
